awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q39650689-978917C7-1178-48B1-904B-9AF4802BE024
Q39650689-978917C7-1178-48B1-904B-9AF4802BE024
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39650689-978917C7-1178-48B1-904B-9AF4802BE024
Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
P2860
Q39650689-978917C7-1178-48B1-904B-9AF4802BE024
BestRank
Statement
http://www.wikidata.org/entity/statement/Q39650689-978917C7-1178-48B1-904B-9AF4802BE024
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
18c59e04d3c5180a93ab4a6620c9db96b3f0c838
P2860
Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m(2) every 21 days in patients with cancer